Citation:Lara PN Jr, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, et al 2006

Citation

Lara PN Jr, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 2006 Nov;1(9):996-1001 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17409985.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Lara PN Jr, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, et al 2006	What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?	Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACP	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the optimal second line therapy in patients with extensive stage small cell lung cancer?|]] (compare critical appraisals)

Cited by

1. What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?